CCA News
CCA Nomination – Health & Medical Research Awards
We’re thrilled to have been nominated as a finalist for the Research Australia Health & Medical Research advocacy awards 2024! It’s fantastic…
PBS listing of Velsipity for treatment of UC
PBS listing of Velsipity for treatment of UC Pfizer Australia has announced the reimbursement of its oral S1P receptor modulator…
Expanded access to funded shingles vaccine
Expanded access to funded shingles vaccine The federal government has expanded access to the shingles vaccine to cover individuals aged…
Ticker LFC interview – CCA CEO Leanne Raven
Watch the full Ticker News interview with CCA CEO Leanne Raven below
New treatment approved by PBAC for pouchitis
Chronic pouchitis looks set to be added to the list of PBS indications for vedolizumab, following a positive recommendation by…
Heath Industry Hub awards 2024: Vote for CCA!
CCA has been nominated as a contender for NGO of the year by the Health Industry Hub! It’s fantastic recognition…
Study: Understanding the perceptions, attitudes, and use of protein supplements amongst adults with ulcerative colitis
Calling all adults with UC, you are invited to participate in a research study conducted by a collaborative group of…
RACGP article: ‘GPs being left out of patients’ IBD treatment’
The Royal Australian College of General Practitioners (RACGP) recently covered CCA’s recommendations and findings from the IBD Paediatric Quality of…
New biological pathway and principal driver of IBD discovered
"Researchers at the Francis Crick Institute, working with UCL and Imperial College London, have discovered a new biological pathway that is a principal driver of inflammatory bowel disease (IBD) and related conditions, and which can be targeted using existing drugs."
ABC News report: Rise in IBD diagnoses
An article recently featured in the ABC which discussed the increasing prevalence of Inflammatory Bowel Disease diagnoses in Australia –…
Cambridge University lab grown “mini guts” study
"Cambridge scientists have grown ‘mini-guts’ in the lab to help understand Crohn’s disease, showing that ‘switches’ that modify DNA in gut cells play an important role in the disease and how it presents in patients. These could in future be used to identify the best treatment for an individual patient, allowing for more precise and personalised treatments."
CCA Healthdirect partnership
CCA recently entered into an Information Partnership with Healthdirect Australia. This partnership allows us to share our resources with a wider audience.